These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38254769)

  • 21. PRAME expression in melanocytic lesions of the nail.
    Parra O; Linos K; Li Z; Yan S
    J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
    Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
    J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRAME Immunoexpression in 275 Cutaneous Melanocytic Lesions: A Double Institutional Experience.
    Cazzato G; Cascardi E; Colagrande A; Belsito V; Lospalluti L; Foti C; Arezzo F; Dellino M; Casatta N; Lupo C; Buongiorno L; Stellacci A; Marrone M; Ingravallo G; Maiorano E; Resta L
    Diagnostics (Basel); 2022 Sep; 12(9):. PubMed ID: 36140597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases.
    Lo Bello G; Pini GM; Giagnacovo M; Patriarca C
    Pathol Res Pract; 2023 Nov; 251():154915. PubMed ID: 37913637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation.
    Fattori A; de la Fouchardière A; Cribier B; Mitcov M
    Hum Pathol; 2022 Mar; 121():19-28. PubMed ID: 34990622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRAME immunohistochemistry for melanoma diagnosis: A STARD-compliant diagnostic accuracy study.
    O'Connor MK; Dai H; Fraga GR
    J Cutan Pathol; 2022 Sep; 49(9):780-786. PubMed ID: 35672262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRAME expression in genital melanocytic lesions - Potential diagnostic pitfall of intermediate expression in atypical genital nevi.
    Ng JKM; Choi PCL; Chow C; Li JJX; To KF
    Pathol Res Pract; 2024 Jun; 260():155404. PubMed ID: 38878667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
    Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
    J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
    Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
    Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
    Lezcano C; Jungbluth AA; Busam KJ
    Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.
    Koch EAT; Erdmann M; Berking C; Kiesewetter F; Kramer R; Schliep S; Heppt MV
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules.
    Schmitt TA; Lee JC; Martinka M; Ko KYC
    J Cutan Pathol; 2023 Mar; 50(3):275-278. PubMed ID: 36398487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant expression of HMB45 and negative PRAME expression in halo nevi.
    Ruby KN; Li Z; Yan S
    J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi.
    Hu J; Cai X; Lv JJ; Wan XC; Zeng XY; Feng ML; Dai B; Kong YY
    Hum Pathol; 2022 Feb; 120():9-17. PubMed ID: 34800527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diffuse PRAME Expression Is Highly Specific for Thin Melanomas in the Distinction from Severely Dysplastic Nevi but Does Not Distinguish Metastasizing from Non-Metastasizing Thin Melanomas.
    Gassenmaier M; Hahn M; Metzler G; Bauer J; Yazdi AS; Keim U; Garbe C; Wagner NB; Forchhammer S
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Melanocyte-Associated Immunohistochemical Markers in Acral Lentiginous Melanoma and Acral Benign Nevi.
    Kim JC; Choi JW; Kim YC
    Am J Dermatopathol; 2023 Nov; 45(11):748-752. PubMed ID: 37856738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
    Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
    Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions.
    Kunc M; Żemierowska N; Skowronek F; Biernat W
    Histopathology; 2023 Jul; 83(1):3-14. PubMed ID: 36942814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
    McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
    J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shedding light on PRAME expression in dysplastic nevi: a cohort study.
    Innocenti L; Scarpitta R; Corraro S; Ortenzi V; Bonadio AG; Loggini B; De Ieso K; Naccarato AG; Fanelli GN; Scatena C
    Virchows Arch; 2023 Dec; ():. PubMed ID: 38112793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.